The 2020 AMR Benchmark Report – concerning findings with questionable framing
The stated intention of the AMR Benchmark report is to guide and incentivise pharmaceutical companies to do more to tackle drug-resistance and provide investors interested in investing in a more ethical and sustainable manner, with a guide to how the pharmaceutical industry “manages risks and opportunities” in the field of AMR. By doing a peer to peer comparison of the companies, they hope to encourage them to compete in exceeding each others efforts in addressing AMR.
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!